XNCR
Xencor Inc

752
Mkt Cap
$1.1B
Volume
421,713.00
52W High
$24.66
52W Low
$6.92
PE Ratio
-8.57
XNCR Fundamentals
Price
$15.22
Prev Close
$15.45
Open
$15.45
50D MA
$15.45
Beta
1.35
Avg. Volume
842,574.68
EPS (Annual)
-$3.58
P/B
1.74
Rev/Employee
$441,972.00
Loading...
Loading...
News
all
press releases
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) CEO Bassil Dahiyat sold 114,377 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.71...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John Desjarlais sold 73,367 shares of the company's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72...
MarketBeat·4h ago
News Placeholder
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) CEO Bassil Dahiyat sold 114,377 shares of the business's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of...
MarketBeat·1d ago
News Placeholder
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has...
MarketBeat·2d ago
News Placeholder
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC
Walleye Capital LLC acquired a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional...
MarketBeat·18d ago
News Placeholder
Xencor Announces Extension of U.S. Patent Term on Certain Xtend Antibodies
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S...
Business Wire·18d ago
News Placeholder
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by Analysts
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat Ratings reports. One...
MarketBeat·27d ago
News Placeholder
Primecap Management Co. CA Has $82.75 Million Holdings in Xencor, Inc. $XNCR
Primecap Management Co. CA lifted its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned...
MarketBeat·1mo ago
News Placeholder
Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR
Bank of Montreal Can grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 160.5% in the second quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·1mo ago
News Placeholder
Xencor (NASDAQ:XNCR) Shares Up 8.7% - What's Next?
Xencor (NASDAQ:XNCR) Trading 8.7% Higher - Still a Buy...
MarketBeat·1mo ago
<
1
2
...
>

Latest XNCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.